Palvella Launches $150M Stock Offering with $22.5M Overallotment Option
Palvella launched a proposed $150 million underwritten public offering of its common stock, with a 30-day option for underwriters to purchase an additional $22.5 million of shares. Net proceeds will fund development of its QTORIN rapamycin and QTORIN pitavastatin programs and general corporate purposes.
1. Proposed Offering Details
Palvella Therapeutics has commenced an underwritten public offering of $150.0 million of its common stock, with an additional 30-day option for underwriters to purchase up to $22.5 million more shares. The offering is subject to market and customary closing conditions with no assurances on final size or timing.
2. Use of Proceeds
The company intends to use net proceeds to advance its clinical programs, specifically the development of QTORIN rapamycin gel and QTORIN pitavastatin, and for working capital, research and development expenses, and other general corporate purposes.
3. Underwriting and Registration
TD Cowen, Cantor, Stifel, Mizuho, LifeSci Capital, Oppenheimer & Co., Canaccord Genuity and H.C. Wainwright are serving as joint bookrunning managers, with Lucid Capital Markets, Jones, Clear Street and Craig-Hallum as co-managers. The offering is being conducted under a shelf registration statement on Form S-3 declared effective on January 29, 2026.
4. Market Reaction
Palvella’s shares surged over 36% on the day of the announcement, reflecting investor enthusiasm for the planned capital raise and its potential to fund key development programs.